StockNews.AI
LENZ
StockNews.AI
161 days

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025

1. LENZ to report Q4 and full-year 2024 results on March 19, 2025. 2. Product candidate LNZ100 targets presbyopia, affecting 1.8 billion globally. 3. FDA set PDUFA date for LNZ100 on August 8, 2025. 4. LENZ's aceclidine eye drop aims to enhance near vision. 5. Webcast available for financial results and corporate updates.

Earnings
+5.67%Current Return
VS
+0.09%S&P 500
$22.5803/11 08:07 AM EDTEvent Start
$23.8603/12 02:43 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming financial results and FDA PDUFA date could boost investor confidence. Historically, biopharmaceutical companies see stock gains leading up to pivotal announcements or product approvals.

How important is it?

The timing of the earnings report and FDA action date indicates significant events that directly affect stock valuation. Given the uniqueness of LENZ's product and its market potential, the impact could be considerable.

Why Short Term?

The immediate effect from the webcast and FDA decision is expected soon, influencing the stock's market position. Past examples show stocks often trend upward ahead of key date announcements.

Related Companies

VRTXRGEN
March 11, 2025 08:00 ET  | Source: LENZ Therapeutics, Inc. SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, March 19, 2025, at 4:30 p.m. EST to report its fourth quarter and full year 2024 financial results and recent corporate highlights. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 9147301. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event. About LENZ TherapeuticsLENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com. Contacts:Dan Chevallard LENZ TherapeuticsIR@LENZ-Tx.com

Related News